Introducing HPV Vaccine in Developing Countries — Key Challenges and Issues

Jan M. Agosti; Sue J. Goldie

doi:10.1056/nejmp078053

May 9, 2007New England Journal of MedicineOpen Access

Introducing HPV Vaccine in Developing Countries — Key Challenges and Issues

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to highlight the need for HPV vaccine introduction to combat cervical cancer deaths in developing countries.
Reviewed data on cervical cancer deaths related to HPV in developing countries
Analyzed evidence for global policy recommendations
Identified key challenges in vaccine implementation
Over 80% of cervical cancer deaths occur in developing countries, totaling 274,000 annually.
Sufficient evidence supports the introduction of HPV vaccine to reduce deaths.
Key challenges include infrastructure, education, and access to healthcare.

Implication

Experts propose global policy recommendations for HPV vaccine introduction, addressing cervical cancer issues in developing countries.

Abstract

Of 274,000 deaths due to cervical cancer each year, more than 80% occur in developing countries. Drs. Jan Agosti and Sue Goldie suggest that there is sufficient evidence to support global policy recommendations for the introduction of HPV vaccine.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Agosti et al. (2007) studied this question.

synapsesocial.com/papers/6a21f5763b8e99975a4e9b74 https://doi.org/10.1056/nejmp078053

View Full Paper

Ask AI

Bookmark

Share

Introducing HPV Vaccine in Developing Countries — Key Challenges and Issues

Key Points

Implication

Abstract

Discussion

Cite This Study

Introducing HPV Vaccine in Developing Countries — Key Challenges and Issues

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading